BB Biotech AG

$57.62

$0.64(1.12%)

BB Biotech AG

BBZA.DE

$57.62

$0.64(1.12%)

BB Biotech AG

BBZA.DE

XETRA

$57.62

$0.64(1.12%)

Chart

Upcoming Earnings

Next report date

Apr 24, 2026

Report period

Q2 2026

EPS Estimate

—

Revenue Estimate

—

Key stats

52-Week Range$57.62

$29.38

$61.28

Market capitalization

$3.20B

Dividend yield (indicated)

3.90%

Price to earnings Ratio (TTM)

-5.77

Basic EPS (TTM)

$-9.18

Net income (TTM)

$-502.51M

Revenue (TTM)

$-201.77M

Avg. volume

10.01K

Beta (1Y)

0.69

Employees

Market capitalization

$3.20B

Dividend yield (indicated)

3.90%

Price to earnings Ratio (TTM)

-5.77

Basic EPS (TTM)

$-9.18

Net income (TTM)

$-502.51M

Revenue (TTM)

$-201.77M

Avg. volume

10.01K

Beta (1Y)

0.69

Employees

Screener Quick Check

About BB Biotech AG

Sector

Healthcare

Industry

Biotechnology

CEO

Daniel Koller

Website

www.bbbiotech.ch

Headquarters

Seestrasse 16, Kusnacht, 8700

IPO Date

2020-06-29

Identifiers

ISINCH0038389992

Description

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The...

Related Stocks

Carl Zeiss Meditec AG

AFX.DE

$27.03Mkt Cap: $2.37B

Healthcare

Medical - Instruments & Supplies

ISIN:DE0005313704

CureVac N.V.

Dividend Overview

Dividend yield (indicated)

3.90%

Dividend per share

$2.06annual

Payout ratio (Earnings)

-22.5%

Payout ratio (FCF)

22.6%

Dividend growth streak

Dividend CAGR (3Y)

-21.2%

Dividend CAGR (5Y)

-11.2%

Dividend CAGR (10Y)

—

Dividend yield (indicated)

3.90%

Dividend per share

$2.06annual

Payout ratio (Earnings)

-22.5%

Payout ratio (FCF)

22.6%

Dividend growth streak

Dividend CAGR (3Y)

-21.2%

Dividend CAGR (5Y)

-11.2%

Dividend CAGR (10Y)

—

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate